Tyme Technologies, Inc. (TYME)
(Delayed Data from NSDQ)
$1.56 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TYME]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
COVID-19 Readout in 1H21; Clinical Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Promising Preclinical Data of SM-88 and TYME-18 at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Continued Clinical Progress With Minimal Impact From COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Advancing SM-88 on Multiple Fronts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Kick-Starting the New Year With Eagle Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Multiple Clinical Study Initiations Slated by YE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Pancreatic Pivotal Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Two Pivotal Pancreatic Studies to Initiate in CY3Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Promising SM-88 Data Update at ESMO GI; Pivotal Study to Start in 3Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Two Pivotal Studies to Start in 2H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
FDA Gives Nod to Initiate Pivotal Phase 3 Study for Pancreatic Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
SM-88 Continues to Show Encouraging Results in nmCRPC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Prostate Cancer Update at ASCO GU; Additional Studies to Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Unwarranted Stock Decline on Positive Clinical Results Creates a Buying Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
SM-88 Moving Forward With Data Readouts and New Studies in 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Clinical Collaboration With PanCAN Could Speed Up SM-88 Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
SM-88 Development Plans in Place; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Phase 2 Study Positioned for Success; Early Results Expected by 1Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S